Hong Kong Small-Caps Report Card: CNTC Int'l Revenue Up 8.3%, Tech-Ophthalmic Drug Nears Approval

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CNTC International (06055.HK) reported 8.3% revenue growth in first-half 2026, driven by expanded exports of next-generation tobacco products. Tech-Ophthalmic (6622.HK) confirmed positive Phase III results for TAB014 in September, positioning for 2027 Q1 regulatory submission.

Weibo (9898.HK) hit 230 million monthly active users in August, with advertising revenue up 15% sequentially. CDB Leasing (1606.HK) initiated its green finance program post-board reshuffle, deploying HKD 8 billion toward renewable energy infrastructure.

GX China Smart (2807.HK) grew assets under management to HKD 20 billion in Q3, a 22% year-on-year increase. CSOP-HSBC US Treasury Bond ETF (3436.HK) yielded 4.7% in October, attracting three consecutive weeks of southbound capital inflows.

Yide Investment (6182.HK) secured a USD 120 million infrastructure deal in Southeast Asia. PhotonTech-P (1879.HK) received HKD 500 million funding from Middle Eastern sovereign wealth fund for AI chip development. Male 岸 Tech (1647.HK) completed blockchain pilot for supply chain finance, boosting transaction efficiency by 40%.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.